| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $73.3M | +164.8% |
| SG&A Expense | $17.6M | +25.0% |
| Operating Income | -$90.9M | -117.7% |
| Pre-tax Income | -$80.6M | -118.1% |
| Income Tax | $0 | — |
| Net Income | -$80.6M | -118.1% |
| EPS (Basic) | -$1.32 | -57.1% |
| EPS (Diluted) | -$1.32 | -57.1% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $33.2M | +24.2% |
| Current Assets | $195.3M | +116.6% |
| Total Assets | $200.2M | +108.7% |
| Current Liabilities | $24.4M | +156.2% |
| Total Liabilities | $28.4M | +99.9% |
| Stockholders' Equity | $171.8M | +110.2% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$70.8M | -111.5% |
| Capital Expenditures | $515K | +214.0% |
| Investing Cash Flow | -$85.4M | -356.0% |
| Financing Cash Flow | $161.9M | — |
| Free Cash Flow | -$71.3M | -112.0% |